Warning: foreach() argument must be of type array|object, bool given in /var/www/html/web/app/themes/studypress-core-theme/template-parts/header/mobile-offcanvas.php on line 20

Kinetic Inhibition Patterns Indicate how the observed \(K_{\mathrm{m}}\) of an enzyme would change in the presence of inhibitors having the given effect on \(a\) and \(\alpha^{\prime}\) : a. \(\alpha>\alpha^{\prime} ; \alpha^{\prime}=1.0\) b. \(\alpha^{\prime}>\alpha\) c. \(\alpha=\alpha^{\prime} ; \alpha^{\prime}>1.0\) d. \(\alpha=\alpha^{\prime} ; \alpha^{\prime}=1.0\)

Short Answer

Expert verified
a: Increase, b: Decrease, c: Unchanged, d: Unchanged.

Step by step solution

01

Recall the Enzyme Kinetics Modification

In enzyme kinetics, under the influence of inhibitors, the apparent Michaelis-Menten constant \(K_{\mathrm{m, app}}\) is given by \(K_{\mathrm{m, app}} = \frac{\alpha K_{\mathrm{m}}}{\alpha^{\prime}}\). Here, \(\alpha\) and \(\alpha^{\prime}\) are modification factors due to competitive and uncompetitive inhibition, respectively.
02

Analyze Situation a: \(\alpha > \alpha^{\prime}\); \(\alpha^{\prime} = 1.0\)

When \(\alpha > \alpha^{\prime}\) and \(\alpha^{\prime} = 1.0\), it implies that only \(\alpha\) impacts the modification (competitive inhibition). Hence, \(K_{\mathrm{m, app}} = \alpha K_{\mathrm{m}}\). The observed \(K_{\mathrm{m}}\) increases.
03

Analyze Situation b: \(\alpha^{\prime} > \alpha\)

If \(\alpha^{\prime} > \alpha\), it suggests predominant uncompetitive inhibition, therefore \(K_{\mathrm{m, app}} = \frac{\alpha K_{\mathrm{m}}}{\alpha^{\prime}}\). \(K_{\mathrm{m, app}}\) will decrease since \(\alpha^{\prime}\) is greater than \(\alpha\).
04

Analyze Situation c: \(\alpha = \alpha^{\prime} > 1.0\)

For \(\alpha = \alpha^{\prime} > 1.0\), both competitive and uncompetitive inhibitions affect equally, so \(K_{\mathrm{m, app}} = K_{\mathrm{m}}\). The observed \(K_{\mathrm{m}}\) remains unchanged.
05

Analyze Situation d: \(\alpha = \alpha^{\prime} = 1.0\)

When \(\alpha = \alpha^{\prime} = 1.0\), there is no inhibition effect, and hence \(K_{\mathrm{m, app}} = K_{\mathrm{m}}\). The observed \(K_{\mathrm{m}}\) remains unchanged.

Unlock Step-by-Step Solutions & Ace Your Exams!

  • Full Textbook Solutions

    Get detailed explanations and key concepts

  • Unlimited Al creation

    Al flashcards, explanations, exams and more...

  • Ads-free access

    To over 500 millions flashcards

  • Money-back guarantee

    We refund you if you fail your exam.

Over 30 million students worldwide already upgrade their learning with Vaia!

Key Concepts

These are the key concepts you need to understand to accurately answer the question.

Michaelis-Menten constant
The Michaelis-Menten constant, often symbolized as \(K_{\mathrm{m}}\), is a crucial concept in enzyme kinetics. This constant helps us understand how efficient an enzyme is at converting a substrate into a product. Put simply, it's the substrate concentration at which the reaction rate is at half its maximum velocity.
Understanding \(K_{\mathrm{m}}\) gives insights into the affinity of an enzyme for its substrate; a low \(K_{\mathrm{m}}\) means high affinity and vice versa.
  • Key to enzyme kinetics: Shows enzyme efficiency
  • Low values mean high affinity for substrates
  • Helps in comparing different enzyme-substrate interactions
When inhibitors are present, apparent changes to \(K_{\mathrm{m}}\) can occur, depending on the nature and type of inhibition, affecting the enzyme’s catalytic action.
Competitive inhibition
Competitive inhibition is when a substance mimics the substrate and competes for the enzyme's active site. This type of inhibition can significantly affect enzyme kinetics by increasing the apparent Michaelis-Menten constant, \(K_{\mathrm{m, app}}\).
Why does this happen? Because the inhibitor, resembling the substrate, occupies the active site, preventing the substrate from binding. The more inhibitor is present, the more the substrate needs to outcompete it, raising the apparent \(K_{\mathrm{m}}\):
  • Directly competes with substrate for active site
  • Raises \(K_{\mathrm{m}}\) since higher substrate concentration is needed
  • Vmax remains unaffected as inhibitor effect reduces with high substrate concentrations
A good example of competitive inhibition is drugs that block enzyme activity by occupying the active site. Despite raising \(K_{\mathrm{m}}\), it doesn’t change the maximum velocity of the reaction, as the inhibition can be overcome by increasing substrate concentration.
Uncompetitive inhibition
Uncompetitive inhibition occurs when the inhibitor only binds to the enzyme-substrate complex, not the free enzyme. This binding affects the enzyme in a way that prevents the reaction from completing, thus influencing both the \(K_{\mathrm{m, app}}\) and the maximum velocity (Vmax) of the reaction.
This particular form of inhibition reduces APK, the apparent constant. It lowers both \(K_{\mathrm{m}}\) and \(V_{\mathrm{max}}\), allowing the system to work on a new level:
  • Bind to enzyme-substrate complex, not free enzyme
  • Decreases both \(K_{\mathrm{m}}\) and \(V_{\mathrm{max}}\)
  • Cannot be overcome by increasing substrate concentration
What is fascinating about uncompetitive inhibition is how it creates a type of balance. Both the affinity and maximum capacity for the substrate lower simultaneously, meaning it reduces the reaction rate under all substrate concentrations.

One App. One Place for Learning.

All the tools & learning materials you need for study success - in one app.

Get started for free

Most popular questions from this chapter

Applying the Michaelis-Menten Equation IV Researchers discover an enzyme that catalyzes the reaction \(\mathrm{X} \rightleftharpoons \mathrm{Y}\). They find that the \(K_{\mathrm{m}}\) for the substrate \(\mathrm{X}\) is \(4 \mu \mathrm{M}\), and the \(k_{\text {cat }}\) is \(20 \mathrm{~min}^{-1}\). a. In an experiment, \([\mathrm{X}]=6 \mathrm{mM}\), and \(V_{0}=480 \mathrm{nM} \mathrm{min}^{-1}\). What was the \(\left[\mathrm{E}_{\mathrm{t}}\right]\) used in the experiment? b. In another experiment, \(\left[\mathrm{E}_{\mathrm{t}}\right]=0.5 \mu \mathrm{M}\), and the measured \(V_{0}=5 \mu \mathrm{M} \mathrm{min}^{-1}\). What was the \([\mathrm{X}]\) used in the experiment? c. The researchers discover that compound \(Z\) is a very strong competitive inhibitor of the enzyme. In an experiment with the same \(\left[E_{t}\right]\) as in (a), but a different \([\mathrm{X}]\), they add an amount of \(\mathrm{Z}\) that produces an \(a\) of 10 and reduces \(V_{0}\) to \(240 \mathrm{nM} \mathrm{min}^{-1}\). What is the \([\mathrm{X}]\) in this experiment? d. Based on the kinetic parameters given, has this enzyme evolved to achieve catalytic perfection? Explain your answer briefly, using the kinetic parameter(s) that define catalytic perfection.

The Effects of Reversible Inhibitors The MichaelisMenten rate equation for reversible mixed inhibition is written as $$ V_{0}=\frac{V_{\max }[\mathrm{S}]}{\alpha K_{\mathrm{m}}+\alpha^{\prime}[\mathrm{S}]} $$ Apparent, or observed, \(K_{\mathrm{m}}\) is equivalent to the [S] at which $$ V_{0}=\frac{V_{\max }}{2 \alpha^{\prime}} $$ Derive an expression for the effect of a reversible inhibitor on apparent \(K_{\mathrm{m}}\) from the previous equation.

Applying the Michaelis-Menten Equation III A research group discovers a new version of happyase, which they call happyase *, that catalyzes the chemical reaction HAPPY \(\rightleftharpoons\) SAD. The researchers begin to characterize the enzyme. a. In the first experiment, with \(\left[E_{t}\right]\) at \(4 \mathrm{~nm}\), they find that the \(V_{\max }\) is \(1.6 \mu \mathrm{M} \mathrm{s}^{-1}\). Based on this experiment, what is the \(k_{\text {cat }}\) for happyase*? (Include appropriate units.) b. In the second experiment, with \(\left[E_{t}\right]\) at \(1 \mathrm{~nm}\) and [HAPPY] at \(30 \mu \mathrm{M}\), the researchers find that \(V_{0}=300 \mathrm{nM} \mathrm{s}^{-1}\). What is the measured \(K_{\mathrm{m}}\) of happyase* for its substrate HAPPY? (Include appropriate units.) c. Further research shows that the purified happyase * used in the first two experiments was actually contaminated with a reversible inhibitor called ANGER. When ANGER is carefully removed from the happyase * preparation and the two experiments are repeated, the measured \(V_{\max }\) in (a) is increased to \(4.8 \mu \mathrm{M} \mathrm{s}^{-1}\), and the measured \(K_{\mathrm{m}}\) in (b) is now \(15 \mu_{\mathrm{M}}\). Calculate the values of \(a\) and \(\alpha^{\prime}\) for ANGER. d. Based on the information given, what type of inhibitor is ANGER?

Properties of an Enzyme of Prostaglandin Synthesis Prostaglandins are one class of the fatty acid derivatives called eicosanoids. Prostaglandins produce fever and inflammation, as well as the pain associated with inflammation. The enzyme prostaglandin endoperoxide synthase, a cyclooxygenase, uses oxygen to convert arachidonic acid to \(\mathrm{PGG}_{2}\), the immediate precursor of many different prostaglandins (prostaglandin synthesis is described in Chapter 21 . Ibuprofen inhibits prostaglandin endoperoxide synthase, thereby reducing inflammation and pain. The kinetic data given in the table are for the reaction catalyzed by prostaglandin endoperoxide synthase in the absence and presence of ibuprofen. a. Based on the data, determine the \(V_{\max }\) and \(K_{\mathrm{m}}\) of the enzyme. \(\begin{array}{ccc}\begin{array}{c}\text { [Arachidonic } \\ \text { acid] }(\mathrm{mM})\end{array} & \begin{array}{c}\text { Rate of formation of } \\\ \mathrm{PGG}_{2}\left(\mathrm{mM} \mathrm{min}^{-1}\right)\end{array} & \begin{array}{c}\text { Rate of formation of } \\ \mathrm{PGG}_{2} \text { with } 10 \mathrm{mg} / \mathrm{mL}\end{array}\end{array}\) \begin{tabular}{ccc} ibuprofen & \(\left(\mathrm{mM}^{-1} \mathrm{~min}^{-1}\right)\) \\ \hline \(0.5\) & \(23.5\) & \(16.67\) \\ \(1.0\) & \(32.2\) & \(30.49\) \\ \(1.5\) & \(36.9\) & \(37.04\) \\ \(2.5\) & \(41.8\) & \(38.91\) \\ \(3.5\) & \(44.0\) & 25 \\ \hline \end{tabular} b. Based on the data, determine the type of inhibition that ibuprofen exerts on prostaglandin endoperoxide synthase.

Dlinical Application of Differential Enzyme Inhibition Human blood serum contains a class of enzymes known as acid phosphatases, which hydrolyze biological phosphate esters under slightly acidic conditions \((\mathrm{pH} .0)\) : Acid phosphatases are produced by erythrocytes and by the liver, kidney, spleen, and prostate gland. The enzyme of the prostate gland is clinically important, because its increased activity in the blood can be an indication of prostate cancer. The phosphatase from the prostate gland is strongly inhibited by tartrate ion, but acid phosphatases from other tissues are not. How can this information be used to develop a specific procedure for measuring the activity of prostatic acid phosphatase in human blood serum?

See all solutions

Recommended explanations on Chemistry Textbooks

View all explanations

What do you think about this solution?

We value your feedback to improve our textbook solutions.

Study anywhere. Anytime. Across all devices.

Sign-up for free